A Phase 2 interventional study of AGN-199201 and AGN-190584 in Presbyopia, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 40 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-12-03.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Presbyopia with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Presbyopia · United States.
Among the 131 studies in Presbyopia with a site in United States, this one is the 67th largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2014, is one of 15 in phase 2, and was the 18th registered.
336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.
Browse Presbyopia studies →8 of the 131 studies in Presbyopia with a site in United States are open now. Recruiting first, the newest first:
Gordon Schanzlin New Vision · Sites in United States
Ages 40+ · Healthy volunteers
Southern College of Optometry · Sites in United States
Ages 18–40 · Healthy volunteers
Southern College of Optometry · Sites in United States
Ages 45–64
VIS, Inc. · Sites in United States
Ages 40+
Bausch & Lomb Incorporated · Sites in United States
Ages 22+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Presbyopia studies recruiting now, 7 (39%) set no upper age limit and 9 (50%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 40 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 20 · Phase 4 8
First in 2003; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is close to the median of 61 across 276 interventional studies indexed under Presbyopia.
Median enrollment 75 across the 120 interventional studies, 46 across the 11 observational. Of the 113 that completed or were terminated, 84 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 131 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 9 studies filed under Presbyopia — fewer than ten, so there is no comparison to draw.
4 of the studies in Presbyopia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06487897Phase 3VIS, Inc.Phase III Presbyopia Correction Using the VIS Opti-K™ System | 2026-12 |
| NCT07638943Gordon Schanzlin New VisionRefitting Satisfied INFUSE One-Day Multifocal Wearers to DAILIES TOTAL1 Multifocal Contact Lenses | 2027-01-31 |
| NCT07860567Dr. Daniel H. Chang, MDClinical Evaluation of Visual Performance, Spectacle Independence, and Patient Satisfaction With TECNIS PureSee Mini-Monovision and TECNIS PureSee-TECNIS Odyssey Mix-Match | 2027-03-01 |
| NCT06060041Bausch & Lomb IncorporatedIC-8 Apthera IOL New Enrollment Post Approval Study | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 131 studies in Presbyopia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Presbyopia in each eye that impacts daily activities.
Exclusion Criteria:
1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
Drug: AGN-199201 · Drug: AGN-199201 Vehicle
1 drop of AGN-190584 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
Drug: AGN-190584 · Drug: AGN-199201 Vehicle
1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
Drug: AGN-199201 · Drug: AGN-190584 · Drug: AGN-199201 Vehicle
1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in both eyes, once and twice daily for 3 days each.
Drug: AGN-199201 · Drug: AGN-190584
1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye
UNVA is assessed without corrective lenses in the non-dominant eye. UNVA is measured using an eye chart and is reported as the number of lines read correctly. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of lines read correctly means that vision has improved. The percentages of patients with at least a 2 or more line improvement in UNVA in the non-dominant eye are presented.
Time frame: Baseline, Day 3
| Milestone | AGN-199201 | AGN-190584 | AGN-199201 + AGN-190584 in One Eye | AGN-199201 + AGN-190584 in Both Eyes |
|---|---|---|---|---|
| Started | 15 | 17 | 16 | 17 |
| Completed | 15 | 16 | 16 | 16 |
| Not completed | 0 | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 |
UNVA is assessed without corrective lenses in the non-dominant eye. UNVA is measured using an eye chart and is reported as the number of lines read correctly. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of lines read correctly means that vision has improved. The percentages of patients with at least a 2 or more line improvement in UNVA in the non-dominant eye are presented.
| Percentage of Patients | AGN-199201 | AGN-190584 | AGN-199201 + AGN-190584 in One Eye | AGN-199201 + AGN-190584 in Both Eyes |
|---|---|---|---|---|
| Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye | 46.7 | 70.6 | 56.3 | 68.8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AGN-199201 | — | 0/15 (0%) | 5/15 (33.3%) |
| AGN-190584 | — | 0/17 (0%) | 4/17 (23.5%) |
| AGN-199201 + AGN-190584 in One Eye | — | 0/16 (0%) | 8/16 (50%) |
| AGN-199201 + AGN-190584 in Both Eyes | — | 0/17 (0%) | 5/17 (29.4%) |
| Event | AGN-199201 | AGN-190584 | AGN-199201 + AGN-190584 in One Eye | AGN-199201 + AGN-190584 in Both Eyes |
|---|---|---|---|---|
| Eyelid RetractionEye disorders | 4/15 | 0/17 | 1/16 | 0/17 |
| HeadacheNervous system disorders | 0/15 | 0/17 | 2/16 | 3/17 |
| Vision BlurredEye disorders | 0/15 | 1/17 | 2/16 | 1/17 |
| Ocular DiscomfortEye disorders | 0/15 | 0/17 | 2/16 | 0/17 |
| Punctate KeratitisEye disorders | 1/15 | 0/17 | 0/16 | 0/17 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/15 | 0/17 | 0/16 | 0/17 |
| Conjunctival HyperaemiaEye disorders | 0/15 | 1/17 | 1/16 | 1/17 |
| Lacrimation IncreasedEye disorders | 0/15 | 1/17 | 1/16 | 1/17 |
| PhotophobiaEye disorders | 0/15 | 0/17 | 1/16 | 0/17 |
| DiscomfortGeneral disorders | 0/15 | 0/17 | 1/16 | 0/17 |
| Age, Continuous(Years) | AGN-199201 | AGN-190584 | AGN-199201 + AGN-190584 in One Eye | AGN-199201 + AGN-190584 in Both Eyes | Total |
|---|---|---|---|---|---|
| Mean | 49.9 ± 3.88 | 49.1 ± 3.47 | 48.7 ± 4.16 | 49.1 ± 3.97 | 49.2 ± 3.81 |
| Sex: Female, Male(Participants) | AGN-199201 | AGN-190584 | AGN-199201 + AGN-190584 in One Eye | AGN-199201 + AGN-190584 in Both Eyes | Total |
|---|---|---|---|---|---|
| Female | 13 | 13 | 7 | 10 | 43 |
| Male | 2 | 4 | 9 | 7 | 22 |
The record gives a start of Jul 2014, a primary completion of Oct 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxymetazoline · AGN-190584